Introduction: The aim of this study was to describe the clinical features and treatment responses of Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) with kidney involvement.
Methods: We retrospectively analyzed patients with RDD and ECD with kidney involvement from 2005 to 2023, evaluating kidney function changes, as well as computed tomography (CT), and metabolic responses.
Results: The study included 4 patients with RDD and 44 with ECD, with median ages of 58 and 51 years, respectively. Patients with RDD lacked kidney symptoms, whereas 27.3% of patients with ECD exhibited lower extremity edema. The median estimated glomerular filtration rate (eGFR) was 80.5 (63-125) in RDD and 100 (22-133) ml/min per 1.73 m in ECD. All patients with RDD had renal masses; 68.2% of ECD cases showed perirenal infiltration. Two patients with RDD received steroids (1 postnephrectomy), and 2 received lenalidomide and dexamethasone (RD) therapy. One patient with RDD (25%) showed eGFR improvement, and 3 (75%) had CT and positron emission tomography (PET)-CT responses. Of 34 patients with ECD, 26 were treated with interferon-alpha, 5 with inhibitor, and 3 with cytarabine. The rates of eGFR improvement, CT response, and PET-CT response were 14.7%, 5.9%, and 52.9%, respectively. Median follow-up was 27.0 months for RDD and 53.0 months for ECD. The 5-year overall survival was 66.7% for RDD and 81.8% for ECD. The median progression-free survival was 18.3 months for RDD and 59.4 months for ECD.
Conclusion: We described details of kidney involvement characteristics and treatment responses in RDD and ECD, highlighting the typical renal mass in RDD and perirenal soft tissue in ECD. Patients with ECD may experience irreversible kidney dysfunction, indicating the critical need for early diagnosis and timely treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725798 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2024.09.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).
Contemp Clin Trials
January 2025
New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, USA; Columbia University Irving Medical Center, 630 West 168(th) St., New York, NY 10032, USA. Electronic address:
Introduction And Background: The three medications approved to address OUD are effective in decreasing opioid use and morbidity and mortality; however, their utility is limited by high rates of dropout from treatment. The CTN-0100 trial will develop an evidence base for strategies to improve retention on buprenorphine and extended-release naltrexone.
Research Design And Methods: The National Drug Abuse Treatment Clinical Trials Network (CTN) study CTN-0100, "Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy" (RDD), is a multicenter, randomized, non-blinded trial enrolling more than a thousand patients from 18 community-based substance use disorder treatment programs.
Pleural Rosai-Dorfman disease complicated with renal clear cell carcinoma: a case report and literature review.
Front Oncol
January 2025
Department of Radiology, Daping Hospital, Army Medical University, Chongqing, China.
Background: Rosai-Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare non-malignant disorder characterized by excessive proliferation of histiocytes, the cause of which remains unknown. Although the lymph nodes are the most commonly affected site, some patients may present with extranodal involvement, particularly in the skin, nasal cavity, eyes, and bones. In this report, we aim to present a unique case of RDD with pleural involvement in a 61-year-old patient.
View Article and Find Full Text PDFRare histopathological diagnosis of malakoplakia and Rosai‑Dorfman disease in the same uterus mimicking malignancy: A case report.
Exp Ther Med
February 2025
Department of Histopathology, Specialty Hospital, Amman 11194, Jordan.
In the present case, a 66-year-old woman presented to the Specialty Hospital (Amman, Jordan) with recurrent post-menopausal bleeding. A pelvic ultrasound scan showed an abnormal endometrial thickness of 8 mm and no adnexal masses. An endometrial biopsy revealed abundant foamy histiocyte infiltration features suggestive of xanthogranulomatous endometritis.
View Article and Find Full Text PDFClinical Spectrum and Outcome of Kidney Involvement in Non-Langerhans Histiocytosis.
Kidney Int Rep
January 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Introduction: The aim of this study was to describe the clinical features and treatment responses of Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) with kidney involvement.
Methods: We retrospectively analyzed patients with RDD and ECD with kidney involvement from 2005 to 2023, evaluating kidney function changes, as well as computed tomography (CT), and metabolic responses.
Results: The study included 4 patients with RDD and 44 with ECD, with median ages of 58 and 51 years, respectively.
Primary intraosseous Rosai-Dorfman disease: Clinicopathological features and an assessment of a possible relationship with IgG4-related disease.
Ann Diagn Pathol
January 2025
Department of Pathology, Peking University People's Hospital, 100044, China.
Rosai-Dorfman disease (RDD) is a rare proliferative disorder of histiocytes, and primary solitary RDD of the bone is extremely rare. Some RDDs exhibit increased immunoglobulin (Ig)G4 positive (IgG4+) plasma cell infiltration and the histopathological features of IgG4-related disease (IgG4-RD). However, the association between RDD and IgG4-RD remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!